Key result
Personalized antiplatelet therapy may reduce adverse events versus standard clopidogrel in PCI.
Why the study?
Does personalized antiplatelet therapy reduce thrombotic events in patients with coronary artery disease undergoing percutaneous coronary intervention?
Does personalized antiplatelet therapy reduce thrombotic events in patients with coronary artery disease undergoing percutaneous coronary intervention?
Personalized antiplatelet therapy guided by platelet assays or utilizing more potent agents may overcome the limitations of standard clopidogrel in patients undergoing PCI.
Does not support immediate practice change for PCI antiplatelet therapy; leaves open efficacy of personalization in randomized trials.
Clopidogrel has decreased the rate of thrombotic events in patients undergoing percutaneous coronary intervention. However, two major limitations of the drug have been involved in the persistence of a relatively high rate of adverse events. The recent literature suggested that improved platelet reactivity inhibition using a higher or tailored dose of clopidogrel, or a more potent agent, could reduce the rate of events. The development of new antiplatelet agents and the increasing availability of platelet assays are likely to profoundly modify current practice and favor personalized antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Bonello et al. (2009) conducted a review in Coronary artery disease. Personalized antiplatelet therapy was evaluated. Personalized antiplatelet therapy using tailored doses or novel agents is likely to modify current practice and reduce adverse events in patients undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: